mitomycin

Trade name: mutamycin

Small moleculeapproved

Approved

Jun 1, 1973

The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation. Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery. — NCATS

Clinical trial activity

231 trials · 261 clinical orgs · 18 marketing orgs

Phase 1
36
Phase 2
159
Phase 3
83
Phase 4
17

Earliest trial started Sep 1, 1991 (NCT00002490)

Timeline

1970s

  1. Jun 1, 1973

    Earliest FDA Approval

  2. Jun 1, 1974

    Bristol-Myers — First NDA Organization

  3. Jun 1, 1974

    Bristol-Myers — NDA Organization

1980s

  1. Aug 24, 1981

    Bristol-Myers Squibb — Marketing Organization

1990s

  1. Jan 1, 1991

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 1994

    Earliest Phase 2 Sponsor(trial)

  3. Apr 19, 1995

    West-Ward Pharmaceutical — Marketing Organization

  4. Apr 19, 1995

    Hikma — Marketing Organization

  5. Nov 29, 1995

    Hospira — Marketing Organization

  6. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

  7. Apr 30, 1998

    Accord Research — Marketing Organization

2000s

  1. Nov 14, 2002

    SuperGen — NDA Secondary Org

2010s

  1. Feb 7, 2012

    Mobius Therapeutics — NDA Secondary Org

  2. Feb 7, 2012

    Glaukos Corporation — Marketing Organization

  3. Oct 13, 2017

    Mylan — Marketing Organization

  4. Oct 13, 2017

    Apicore — Marketing Organization

2020s

  1. Apr 15, 2020

    UroGen Pharma — Marketing Organization

  2. Apr 15, 2020

    UroGen Pharma — NDA Secondary Org

  3. Oct 20, 2021

    Gland Pharma Ltd — Marketing Organization

  4. Oct 20, 2021

    Fosun — Marketing Organization

  5. Sep 6, 2022

    Eu Yan Sang — Marketing Organization

  6. Sep 6, 2022

    Meitheal — Marketing Organization

  7. Oct 30, 2023

    Eugia Pharma — Marketing Organization

  8. Apr 5, 2024

    Fresenius — Marketing Organization

Indications

Studied for

Mechanism of action

  • DNAINHIBITOR

    DNA inhibitor

Approval history

  • approvedJun 1, 1973

Chemistry & pharmacology

Loading structure…

SMILES

CO[C@]12[C@H]3N[C@H]3CN1C4=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C4=O
Mol. weight
334.3272 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

Yes

Black box warningProdrug

Sources

Also known as

  • 7-amino-9alpha-methoxymitosane
  • 7-amino-9alpha-methoxymitosane
  • ametycine
  • ametycine
  • mitamycin
  • mitamycin
  • mitocin-c
  • mitocin-c
  • mitogel
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin
  • mitomycin c
  • mitomycin c
  • mitomycin c
  • mitomycin c
  • mitomycin c
  • mitomycin-c
  • mitomycin-c
  • mitosol
  • mitosol
  • mitozytrex
  • mitozytrex
  • mmc
  • mmc
  • mutamycin
  • mutamycin
  • mutamycin
  • mutamycin
  • mytozytrex
  • mytozytrex
  • nsc-26980
  • nsc-26980
  • promitil

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07271355Phase 3Jul 1, 2026City of Hope National Medical Center, National Cancer Institute (NCI)
NCT06783491Phase 3Dec 31, 2025Spanish Association of Surgeons (AEC), Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Universidad de Cordoba
NCT07189793Phase 2Oct 31, 2025Wenzhou Medical University
NCT06919965Phase 3Sep 10, 2025
NCT07097142Phase 3Aug 14, 2025NRG Oncology
NCT06774131Phase 3May 2, 2025UroGen Pharma
NCT06770582Phase 2Mar 7, 2025National Cancer Institute (NCI), NRG Oncology
NCT06781879Phase 4Feb 24, 2025Aarhus University, Danish Cancer Society, Medac
NCT06704191Phase 1/Phase 2 (Phase 2)Dec 6, 2024Mayo Clinic, National Center for Advancing Translational Science (NCATS)
NCT06680245Phase 3Dec 1, 2024University of Western Ontario
NCT06696794Phase 3Dec 1, 2024Huazhong University of Science and Technology
NCT06227065Phase 2Oct 31, 2024University of Bern
NCT06513065Phase 3Sep 30, 2024Moorgreen Hospital, Southampton
NCT06331299Phase 3Aug 29, 2024UroGen Pharma
NCT06478862Phase 2Jun 13, 2024Ben Gurion University, Hebrew University, Lipomedix Pharmaceuticals Inc., Technion University, Tel Aviv University
NCT06319820Phase 3Apr 18, 2024Johnson and Johnson
NCT06211764Phase 3Apr 9, 2024
NCT06944132N/AApr 1, 2024Benha University
NCT06233877Phase 2Mar 15, 2024Hirschfeld Oncology
NCT05979909Phase 1Sep 30, 2023McMaster University
Showing 20 of 231 trials
Page 1 / 12

Organizations

Research & Development (261)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government351131995
UroGen PharmaFor profit111032014
Mayo ClinicAcademic/Hospital7421997
Shahid Beheshti University of Medical SciencesAcademic/Hospital6642007
University of LondonAcademic/Hospital6331991
European Organisation for Research and Treatment of CancerAcademic/Hospital5421997
Harvard UniversityAcademic/Hospital5131998
Medical Research CouncilGovernment5321991
University of Texas at HoustonAcademic/Hospital5431998
Johns Hopkins UniversityAcademic/Hospital4422005
Lipomedix Pharmaceuticals Inc.For profit4422012
NRG OncologyAcademic/Hospital4122006
University of Rome Tor VergataAcademic/Hospital4421994
Aeon Astron Europe B.V.For profit3232009
Duke UniversityAcademic/Hospital3322008
ECOG-ACRIN Cancer Research GroupAcademic/Hospital3122009
Hebrew UniversityAcademic/Hospital3022019
Institut Gustave RoussyAcademic/Hospital3111996
Medical Enterprises Europe B.V.For profit3312002
Pro Top & Mediking Company LimitedFor profit3322007
261 organizations
Page 1 / 14

Marketing (20)

OrganizationOrg typeRelationshipDate
Accord ResearchFor profitMKTGApr 30, 1998
ApicoreFor profitMKTGOct 13, 2017
Bristol-MyersFor profitNDAJun 1, 1974
Bristol-Myers SquibbFor profitMKTGAug 24, 1981
Eu Yan SangFor profitMKTGSep 6, 2022
Eugia PharmaFor profitMKTGOct 30, 2023
FosunFor profitMKTGOct 20, 2021
FreseniusFor profitMKTGApr 5, 2024
Gland Pharma LtdFor profitMKTGOct 20, 2021
Gland Pharma LtdFor profitSYNOct 20, 2021
Glaukos CorporationFor profitMKTGFeb 7, 2012
HikmaFor profitMKTGApr 19, 1995
HospiraFor profitMKTGNov 29, 1995
MeithealFor profitMKTGSep 6, 2022
Mobius TherapeuticsFor profitNDA2Feb 7, 2012
MylanFor profitMKTGOct 13, 2017
SuperGenFor profitNDA2Nov 14, 2002
UroGen PharmaFor profitMKTGApr 15, 2020
UroGen PharmaFor profitNDA2Apr 15, 2020
West-Ward PharmaceuticalFor profitMKTGApr 19, 1995